Ultragenyx Pharmaceutical (RARE) Goodwill & Intangibles (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Goodwill & Intangibles data on file, last reported at $218.0 million in Q1 2026.

• Goodwill & Intangibles for Q1 2026 came in at $218.0 million, down 1.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $218.0 million (down 1.33% YoY), and the FY2025 annual result was $220.0 million, down 0.9% from the prior year.
• Goodwill & Intangibles fell to $218.0 million in Q1 2026 per RARE's latest filing, from $220.0 million in the prior quarter.
• Over five years, Goodwill & Intangibles peaked at $222.0 million in Q4 2024 and troughed at $201.7 million in Q3 2023.
• A 5-year average of $210.6 million and a median of $209.5 million in 2024 frame the typical range for Goodwill & Intangibles.
• The sharpest annual moves came in 2022 and 2026: Goodwill & Intangibles advanced 16.73% in 2022, then retreated 1.33% in 2026.
• A 5-year view of Goodwill & Intangibles shows it stood at $204.5 million in 2022, then climbed by 3.01% to $210.7 million in 2023, then climbed by 5.37% to $222.0 million in 2024, then declined by 0.9% to $220.0 million in 2025, then declined by 0.91% to $218.0 million in 2026.
• Business Quant data shows RARE's Goodwill & Intangibles at $218.0 million in Q1 2026, $220.0 million in Q4 2025, and $217.3 million in Q3 2025.